T1	p 178 197	diabetic patients :
T2	p 676 746	, 360 diabetic patients with coronary artery disease were treated with
T3	p 1167 1175	patients
T4	p 2458 2468	patients .
T5	p 2559 2607	diabetic patients with coronary artery disease .
T6	i 19 56	triglyceride/high-density lipoprotein
T7	i 119 131	pioglitazone
T8	i 216 225	PERISCOPE
T9	i 228 240	Pioglitazone
T10	i 451 463	pioglitazone
T11	i 582 594	Pioglitazone
T12	i 628 639	glimepiride
T13	i 747 774	pioglitazone or glimepiride
T14	i 796 805	PERISCOPE
T15	i 808 820	Pioglitazone
T16	i 1568 1580	pioglitazone
T17	i 1758 1769	glimepiride
T18	i 2356 2368	pioglitazone
T19	o 45 68	lipoprotein cholesterol
T20	o 467 487	atheroma progression
T21	o 559 579	atheroma progression
T22	o 934 954	atheroma progression
T23	o 1067 1118	percent atheroma volume , and total atheroma volume
T24	o 1197 1349	increases in high-density lipoprotein cholesterol ( HDL-C ) and reductions in glycated hemoglobin , triglycerides , and C-reactive protein . Significant
T25	o 1396 1439	percent atheroma volume and triglycerides (
T26	o 1464 1488	triglyceride/HDL-C ratio
T27	o 1515 1540	and glycated hemoglobin (
T28	o 1598 1635	low-density lipoprotein cholesterol (
T29	o 1709 1723	apolipoprotein
T30	o 1772 1805	Substantial atheroma regression ,
T31	o 1818 1829	progression
T32	o 1860 1887	relative increases in HDL-C
T33	o 1941 1957	in triglycerides
T34	o 1995 2019	triglyceride/HDL-C ratio
T35	o 2067 2091	in glycated hemoglobin (
T36	o 2245 2270	percent atheroma volume (
T37	o 2286 2309	total atheroma volume (
T38	o 2425 2445	atheroma progression